Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), announced that Chief Medical Officer Amir Inamdar will participate in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference. The conference takes place June 15-16, 2026, with the fireside chat available on demand beginning June 15 at 7:00 a.m. EDT.
This presentation is significant as it provides a platform for Helus Pharma to highlight its pipeline of proprietary NSAs, which are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company is addressing large unmet needs in mental health, particularly for individuals suffering from depression, anxiety, and other conditions. Helus Pharma’s lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder. The company also has an extensive research portfolio of investigational NSAs.
The H.C. Wainwright conference is a key event for the neuropsychiatric industry, attracting investors, analysts, and researchers. Inamdar’s participation could influence investor sentiment and provide updates on clinical progress. For the industry, Helus Pharma’s approach—focusing on serotonergic agonists to enhance neuroplasticity—represents a novel mechanism that could differentiate its therapies from existing treatments. If successful, these drugs could offer durable improvements for patients who do not respond adequately to current antidepressants or anxiolytics.
The implications for patients are substantial. Major depressive disorder and generalized anxiety disorder are prevalent conditions with significant morbidity. Current treatments often have limited efficacy or side effects. Helus Pharma’s NSAs aim to provide a new option that may lead to better outcomes. The Breakthrough Therapy Designation for HLP003 underscores the potential for this drug to address an unmet medical need.
For investors, the conference provides an opportunity to assess the company’s progress. Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland. The company’s stock performance could be influenced by updates on clinical trials and regulatory milestones. The full press release is available at https://ibn.fm/KsnJW.
In summary, the fireside chat at the H.C. Wainwright conference is a chance for Helus Pharma to communicate its vision and data to a broad audience. The company’s focus on NSAs and neuroplasticity could reshape treatment paradigms for depression and anxiety, making this a notable event for stakeholders.
